Related Experiment Videos
Third-generation oral contraceptives and thromboembolism risk
1Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA.
Obstetrics and Gynecology
|June 1, 1997
Summary
Recent studies suggest oral contraceptives (OCs) with third-generation progestins may increase venous thromboembolism risk. However, observational biases limit interpretation, and OCs remain safe and effective.
Area of Science:
- Reproductive Health
- Pharmacovigilance
- Epidemiology
Background:
- Observational studies link third-generation oral contraceptives (OCs) containing gestodene and desogestrel to increased nonfatal venous thromboembolic (VTE) risk.
- The clinical significance of these findings is debated due to the observational nature of the studies and potential biases.
Purpose of the Study:
- To critically evaluate the evidence regarding the association between third-generation OCs and VTE.
- To discuss the limitations of current studies and their impact on interpreting causality.
Main Methods:
- Review and analysis of existing observational studies on OC use and VTE.
- Assessment of potential biases, including case selection and confounding factors.
Main Results:
- Observational studies indicate a potential increased risk of VTE with third-generation OCs.
- Significant biases identified in existing studies, particularly regarding the selection of VTE cases (primarily hospitalized patients).
- Lack of a clear biological mechanism supporting an increased risk with third-generation OCs.
Conclusions:
- The causality of the observed association between third-generation OCs and VTE remains uncertain due to study limitations.
- Current evidence does not definitively establish a causal link; oral contraceptives are considered safe and effective.
- Further research is necessary to clarify the relationship between third-generation OCs and thromboembolic disease. Women should receive comprehensive information on all OC risks.